FNCHQ (Finch Therapeutics Group) FCF Yield %: -110.23 (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FNCHQ Finch Therapeutics Group Inc FNCHQ
12 GF Score
Price $10.20
View Full Analysis

What is Finch Therapeutics Group FCF Yield %?

Finch Therapeutics Group FNCHQ 12 FCF Yield % is -110.23 as of Aug. 19, 2026. GuruFocus rates FNCHQ with a GF Score™ of 12/100.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Finch Therapeutics Group's Trailing 12-Month Free Cash Flow is $-18.06 Mil, and Market Cap is $16.38 Mil. Therefore, Finch Therapeutics Group's FCF Yield % for today is -110.23%.

The historical rank and industry rank for Finch Therapeutics Group's FCF Yield % or its related term are showing as below:

FNCHQ' s FCF Yield % Range Over the Past 10 Years
Min: -110.23   Med: 0   Max: 0
Current: -110.23


FNCHQ's FCF Yield % is not ranked
in the Biotechnology industry.
Industry Median: -9.385 vs FNCHQ: -110.23

Finch Therapeutics Group's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.


Finch Therapeutics Group FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Finch Therapeutics Group FCF Yield % Related Terms


Finch Therapeutics Group FCF Yield % Historical Data

* Premium members only.

The historical data trend for Finch Therapeutics Group's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Finch Therapeutics Group FCF Yield % Chart

Finch Therapeutics Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
0.00 0.00 -17.54 -333.93 -543.41

Finch Therapeutics Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -267.54 -253.12 -255.69 -417.84 -859.19

FNCHQ vs CRIS, LSB, RANI: FCF Yield % Comparison

For the Biotechnology subindustry, Finch Therapeutics Group's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Finch Therapeutics Group FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Finch Therapeutics Group's FCF Yield % falls into.


FNCHQ
12GF Score
Finch Therapeutics Group Inc FNCHQ
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Finch Therapeutics Group FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Finch Therapeutics Group's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-31.505 / 5.79766
=-543.41%

Finch Therapeutics Group's annualized FCF Yield % for the quarter that ended in Jun. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-4.726 * 4 / 2.20022
=-859.19%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -110.23 mean?
Finch Therapeutics Group (FNCHQ) has a FCF Yield % of -110.23 as of Aug. 19, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Finch Therapeutics Group and its competitors.
Is Finch Therapeutics Group's FCF Yield % too high?
Finch Therapeutics Group's current FCF Yield % is -110.23. Overall, Finch Therapeutics Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Finch Therapeutics Group's FCF Yield % compare to CRIS and LSB?
Finch Therapeutics Group's FCF Yield % of -110.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Finch Therapeutics Group and its competitors. Finch Therapeutics Group's current FCF Yield % is -110.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Finch Therapeutics Group stock overvalued right now?
Finch Therapeutics Group (FNCHQ) has a current FCF Yield % of -110.23. The current FCF Yield % is -110.23. Finch Therapeutics Group's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Finch Therapeutics Group (FNCHQ), the current FCF Yield % is -110.23 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Finch Therapeutics Group Business Description

Address 75 State Street, Suite 100, Boston, MA, USA, 02109
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
12GF Score

Get the complete analysis for FNCHQ

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.20
Price